How to buy Centessa Pharmaceuticals plc American Depositary Shares stock | $16.21

Centessa Pharmaceuticals plc American Depositary Shares is a biotechnology business based in the US. Centessa Pharmaceuticals plc American Depositary Shares shares (CNTA) are listed on the NASDAQ and all prices are listed in US Dollars.

Centessa Pharmaceuticals plc American Depositary Shares stock price (NASDAQ: CNTA)

Use our graph to track the performance of CNTA stocks over time.

Centessa Pharmaceuticals plc American Depositary Shares shares at a glance

• Key figures

Information last updated 2021-10-17.

Latest market close	$16.21
52-week range	$13.34 - $26.90
50-day moving average	$18.62
200-day moving average	$20.75
Wall St. target price	$38.67
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-3.27

Buy Centessa Pharmaceuticals plc American Depositary Shares shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Centessa Pharmaceuticals plc American Depositary Shares stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Centessa Pharmaceuticals plc American Depositary Shares price performance over time

Historical closes compared with the close of $16.21 from 2021-10-18

1 week (2021-10-13)	0.62%
1 month (2021-09-20)	-10.93%
3 months (2021-07-20)	-23.97%
6 months (2021-04-16)	N/A

1 year (2020-10-16)	N/A
2 years (2019-10-16)	N/A
3 years (2018-10-19)	7800
5 years (2016-10-16)	N/A

Centessa Pharmaceuticals plc American Depositary Shares financials

Gross profit TTM	$0
Return on assets TTM	0%
Return on equity TTM	-9999999%
Profit margin	0%
Book value	$6.51
Market capitalisation	$1.5 billion

TTM: trailing 12 months

Shorting Centessa Pharmaceuticals plc American Depositary Shares shares

There are currently 1.2 million Centessa Pharmaceuticals plc American Depositary Shares shares held short by investors – that's known as Centessa Pharmaceuticals plc American Depositary Shares's "short interest". This figure is 37.7% up from 854,397 last month.

There are a few different ways that this level of interest in shorting Centessa Pharmaceuticals plc American Depositary Shares shares can be evaluated.

Centessa Pharmaceuticals plc American Depositary Shares's "short interest ratio" (SIR)

Centessa Pharmaceuticals plc American Depositary Shares's "short interest ratio" (SIR) is the quantity of Centessa Pharmaceuticals plc American Depositary Shares shares currently shorted divided by the average quantity of Centessa Pharmaceuticals plc American Depositary Shares shares traded daily (recently around 135062.80137773). Centessa Pharmaceuticals plc American Depositary Shares's SIR currently stands at 8.71. In other words for every 100,000 Centessa Pharmaceuticals plc American Depositary Shares shares traded daily on the market, roughly 8710 shares are currently held short.

To gain some more context, you can compare Centessa Pharmaceuticals plc American Depositary Shares's short interest ratio against those of similar companies.

• AbbVie (ABBV.US): 1.43
• Pfizer (PFE.US): 1.98

However Centessa Pharmaceuticals plc American Depositary Shares's short interest can also be evaluated against the total number of Centessa Pharmaceuticals plc American Depositary Shares shares, or, against the total number of tradable Centessa Pharmaceuticals plc American Depositary Shares shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Centessa Pharmaceuticals plc American Depositary Shares's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Centessa Pharmaceuticals plc American Depositary Shares shares in existence, roughly 10 shares are currently held short) or 0.0375% of the tradable shares (for every 100,000 tradable Centessa Pharmaceuticals plc American Depositary Shares shares, roughly 38 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Centessa Pharmaceuticals plc American Depositary Shares.

Find out more about how you can short Centessa Pharmaceuticals plc American Depositary Shares stock.

Centessa Pharmaceuticals plc American Depositary Shares share dividends

We're not expecting Centessa Pharmaceuticals plc American Depositary Shares to pay a dividend over the next 12 months.

You may also wish to consider:

• AbbVie (ABBV.US) (4.66% forward annual dividend yield)
• Pfizer (PFE.US) (3.7% forward annual dividend yield)

Centessa Pharmaceuticals plc American Depositary Shares overview

Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers life-altering and life-enhancing medicines to patients. Its products pipeline include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase 3 clinical development for the treatment of autosomal dominant polycystic kidney disease; SerpinPC, an activated protein C inhibitor, which is in Phase 2a clinical development for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody expected to enter a Phase 2 clinical trial for the treatment of cutaneous squamous cell carcinoma, as well as is being considered for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase 1 clinical development for the treatment of alpha-1-antitrypsin deficiency. The company's preclinical product candidates comprise ZF887 for alpha-1-antitrypsin deficiency; MGX292 for pulmonary arterial hypertension; CBS001 for idiopathic pulmonary fibrosis; CBS004 for systemic sclerosis and lupus; LB1 and LB2 for solid tumors; Oral OX2R Agonist and Intranasal OX2R Agonist for narcolepsy type 1; Dual STAT3/5 Degrader for hematological malignancies; EGFR Ex20 and EGFR-C797S inhibitors for non-small cell lung cancer; and next generation EGFR inhibitors. The company was formerly known as United Medicines Biopharma Limited and changed its name to Centessa Pharmaceuticals Limited in February 2021. Centessa Pharmaceuticals Limited was incorporated in 2020 and is based in Cambridge, the United Kingdom. .

Frequently asked questions

What percentage of Centessa Pharmaceuticals plc American Depositary Shares is owned by insiders or institutions?
Currently 1.993% of Centessa Pharmaceuticals plc American Depositary Shares shares are held by insiders and 55.263% by institutions. When does the fiscal year end for Centessa Pharmaceuticals plc American Depositary Shares?
Centessa Pharmaceuticals plc American Depositary Shares's fiscal year ends in December. Where is Centessa Pharmaceuticals plc American Depositary Shares based?
Centessa Pharmaceuticals plc American Depositary Shares's address is: The Dorothy Hodgkin Building Babraham, Cambridge, United Kingdom, CB22 3FH What is Centessa Pharmaceuticals plc American Depositary Shares's ISIN number?
Centessa Pharmaceuticals plc American Depositary Shares's international securities identification number is: US1523091007